Von Willebrand Disease clinical trials

Explore recruiting von willebrand disease clinical trials.

Recruiting von willebrand disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Von Willebrand Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients with Type 3 Von Willebrand Disease

Belgium, Sweden, Spain, Germany, France, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients with von Willebrand Disease (VIVID-6)

Austria, Italy, Ireland, Germany, Finland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and Safety of BT200 (rondaptivon pegol) in Patients with Type 2B von Willebrand disease

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with Vonicog Alfa (rVWF) in Children Diagnosed With Severe von Willebrand disease.

Italy, France, Ireland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed with Severe von Willebrand Disease

France, Spain, Austria, Belgium, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Netherlands, Sweden, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Von Willebrand Disease trials by city

Von Willebrand Disease in Toronto Von Willebrand Disease in Vancouver Von Willebrand Disease in Montreal Von Willebrand Disease in Calgary Von Willebrand Disease in Edmonton Von Willebrand Disease in Ottawa Von Willebrand Disease in Winnipeg Von Willebrand Disease in Quebec City Von Willebrand Disease in Hamilton Von Willebrand Disease in Kitchener Von Willebrand Disease in London Von Willebrand Disease in Halifax Von Willebrand Disease in New York Von Willebrand Disease in Los Angeles Von Willebrand Disease in Chicago Von Willebrand Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease